Stryker close to premarket approval (PMA) for bone graft substitute
This article was originally published in Clinica
Executive Summary
Stryker's 11-year research project on human osteogenic protein substances that play a direct role in skeletal development is moving closer to a payoff. Company chairman and CEO John Brown said Stryker hopes to submit a PMA application sometime late this year for its OP-1 bone growth device, a human recombinant protein that acts as a bone graft substitute.